Investigating how gene interactions with tobacco carcinogens affect lung cancer risk
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention
This study is looking at how certain genes and tobacco chemicals work together to affect the risk of lung cancer in smokers, and it will help identify people who might be more at risk based on their unique body responses to tobacco.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11240741 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific genetic factors interact with tobacco-related carcinogens to influence lung cancer risk. It examines the metabolism of a tobacco-specific nitrosamine, NNK, and its metabolites, particularly NNAL, in smokers. By analyzing urine samples and genetic markers, the study aims to identify individuals at higher risk for lung cancer based on their unique biological responses to tobacco exposure. The research will involve multiple populations to ensure diverse representation and robust findings.
Who could benefit from this research
Good fit: Ideal candidates for this research include smokers and former smokers who may have genetic variations affecting their metabolism of tobacco carcinogens.
Not a fit: Patients who have never smoked or do not have genetic markers related to tobacco carcinogen metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized prevention strategies for lung cancer based on genetic susceptibility to tobacco carcinogens.
How similar studies have performed: Previous research has shown promising results in identifying genetic markers associated with cancer risk, suggesting that this approach could yield valuable insights.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Lazarus, Philip — State University of New York at Buffalo
- Study coordinator: Lazarus, Philip
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.